Table 4 Outcome, recurrence, and side effects of systemic treatment of conjunctival lymphoma
From: Classification, diagnosis, and management of conjunctival lymphoma
Therapy type | Author | Year of publication | Number of eyes | Laterality | Percentage of cases with preexisting or concurrent systemic disease | Histologic subtype | Response rate (CR + PR) | Follow up (months) | Local recurrence rate | Side effects |
|---|---|---|---|---|---|---|---|---|---|---|
Chemotherapy | Baldini et al. [53] (Chlorambucil) | 1998 | 1 | Unilateral | 0% | EMZL | 100% | 140 | 0% | Â |
Bellisi et al. [116] (Adriamycin, Bleomycin, Cyclophosphamide, Prednisone) | 1982 | 5 | 3 unilateral; 1 bilateral | 0% | DWDLL (50%); DPDLL (50%) (unspecified laterality) | 100% | 37 (median) | 20% | Â | |
Seker et al. [39] (CVP) | 2010 | 2 | Bilateral | 0% | EMZL | 100% | 28 | 0% | Â | |
IV Rituximab | Annibali et al. [117] | 2015 | 5 | 3 unilateral; 1 bilateral | 0% | EMZL (100%) | 100% | 29 (median) | 0% | VZV reactivation (1 patient) |
Celiker et al. [118] | 2018 | 2 | Bilateral | 0% | EMZL | 100% | 22 | 0% | Â | |
Ferreri et al. [119] | 2005 | 3 | 2 unilateral; 1 bilateral | 33% | EMZL (100%) | 67% | 5 (median) | 67% | Â | |
Nückel et al. [120] | 2004 | 2 | Unilateral | 0% | EMZL (100%) | 100% | 31 (median) | 0% | Reactivation of hepatitis B (1 patient) | |
Rigacci et al. [121] (rituximab-Chlorambucil) | 2007 | 4 | Unilateral | 0% | EMZL (75%); FL (25%) | 100% | 33 (median) | 0% | Â | |
Salepçi et al. [122] | 2009 | 2 | Bilateral | 0% | EMZL | 100% | 16 | 0% |  | |
Sallak et al. [123] (Rituximab-Bendamustine) | 2014 | 1 | Unilateral | 100% | EMZL | 100% | 36 | 0% | Â | |
Tuncer et al. [124] | 2015 | 6 | Unilateral | 0% | EMZL (83%); FL (17%) | 100% | 25 | 50% | Â | |
Wall et al. [125] | 2015 | 2 | Bilateral | 0% | FL | 100% | 15 | 0% | Â | |
Zinzani et al. [126] | 2005 | 1 | Unilateral | 0% | FL | 100% | 5 | 0% | Â | |
90Y-ibritumomab tiuxetan | Esmaeli et al. [127] | 2009 | 5 | Unilateral | 0% | EMZL (100%) | 100% | 27 (median) | 0% | Grades I-II pancytopenia (100%), mild fatigue, nausea, headache |
Oellers et al. [128] | 2012 | 1 | Unilateral | 100% | EMZL | 100% | 3 | 0% | Â |